Skip to main content

Top 8 AMCs have these 4 largecaps in their portfolio

 Infosys fired almost on all cylinders in June quarter earnings, which gave confidence to investors and as a result six out of 10 fund houses raised exposure to the stock last month.

 

Mutual funds, also known as asset management companies (AMCs), are key investors in equity markets. They put investors' money in several segments, including equities and debts. In the last few years, whenever the market corrected sharply, they remained supportive.

But, in the last couple of months, they have been net sellers, probably preferring to book profits given the 50 percent rally in markets from March lows. In the last two months, MFs sold nearly Rs 11,000 crore worth of shares, including Rs 7,232 crore in July.

Foreign institutional investors (FIIs), however, were net buyers, who bought nearly Rs 32,000 crore worth of shares in the two-month period, including Rs 8,590.13 crore in July. If we go back a bit more, FIIs have been net buyers in the April-July period.

The market rose more than 7 percent in June as well as July. It seems to have priced in all positives given the data points published during the unlocking period and June quarter earnings report card along with major liquidity boost, experts say.

Given the rally, mutual funds rejigged their exposure to some stocks but four bluechips—Reliance Industries, Infosys, HDFC Bank and ICICI Bank— have remained a constant in their holdings.

The country's second-largest IT services company Infosys and top private sector lender HDFC Bank were held by all top 10 mutual fund houses in July. Billionaire Mukesh-Ambani-owned Reliance Industries and India's second-largest private sector lender ICICI Bank were held by nine of the 10 AMCs.

Overall, eight AMCs—SBI AMC, HDFC AMC, ICICI Prudential AMC, Nippon AMC, UTI AMC, Aditya Birla Sunlife AMC, Kotak AMC and Mirae AMC—held all these four stocks.

These AMCs held more than Rs 2 lakh crore worth of shares in these four companies, including HDFC Bank (Rs 56,192 crore) and Reliance Industries (Rs 51,820 crore).


These four stocks have rallied smartly from their March lows, with Reliance Industries leading the charge (up 139 percent), Infosys (82 percent), HDFC Bank (34 percent) and ICICI Bank (27 percent).

Reliance (up 21 percent) and Infosys (up 31 percent) continued their run in July as well but ICICI Bank was down 1 percent and HDFC Bank 3 percent during the month.

Given the rally, eight of nine AMCs reduced their exposure to Reliance Industries in July. More than Rs 1.5 lakh crore of investment by global investors in Jio Platforms, a flourishing telecom business and its debt-free status pushed RIL stock price to record high in July. RIL became the first company to hit Rs 14-lakh crore (including its partly paid-up shares) market cap.

Infosys fired almost on all cylinders in the June quarter earnings, which gave confidence to investors and as a result, six of the 10 fund houses raised exposure to the stock in July. In the case of ICICI Bank and HDFC Bank, which reported good sets of earnings despite moratorium, five AMCs each increased their exposure.

"Market is being driven majorly by RIL. Also, technology stocks were favourites among AMCs. Growth anticipation and better Q1FY21 results led the rally. In my opinion, these stocks may continue to generate good returns in the long term. Amid uncertainty over earnings and sustained profitability, institutions have preferred heavyweights over broader indices," Gaurav Garg, Head of Research at CapitalVia Global Research told Moneycontrol.

The broader market has not performed well over the last three years. Since 2018 January, the Nifty has remained flat while the broader market as represented by midcap and smallcap indices have severely underperformed the Nifty.

Vineeta Sharma, Head of Research at Narnolia Financial Advisors agrees with Garg. "The market internals are highly skewed in the favour of selective largecap stocks and the same is being reflected when we see the mutual funds holdings," she said.

Till a broader economic recovery and earnings growth is seen in Indian companies, this situation will continue, she said.

Both experts favour holding these stocks for the long term.

Garg said investors should have 60 percent exposure in bluechips and rest in broader indices. "In my opinion, they should continue to hold them for mid to long term."

These stable good quality companies are a must-own for any investor for the long term, though once broader economy improves, it would be advisable to include growth-producing mid and small-cap stocks as well, Sharma said.

Apart from these four stocks, seven of 10 AMCs held Bharti Airtel in July and six have exposure to Axis Bank. Five fund houses also have exposure to Kotak Mahindra Bank, TCS and ITC.

HUL, SBI and NTPC were held by four out of 10 AMCs, while housing finance major HDFC is held by three fund houses.

Note: The data of top 10 AMCs and their exposure to stocks in July has been taken from ICICI Direct's research report of August 13, 2020.

 

Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com/SD Solutions advises users to check with certified experts before taking any investment decisions.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...